AWA
MRNA icon

Arkadios Wealth Advisors’s Moderna MRNA Stock Holding History

Arkadios Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
15,033
-2,824
-16% -$146K 0.02% 782
2026
Q1 		$907K Sell
17,857
-6,489
-27% -$303K 0.01% 836
2025
Q4 		$718K Buy
24,346
+11,215
+85% +$305K 0.01% 848
2025
Q3 		$339K Buy
13,131
+32
+0.2% +$893 0.01% 1109
2025
Q2 		$361K Sell
13,099
-1,045
-7% -$27.5K 0.01% 980
2025
Q1 		$401K Buy
14,144
+1,879
+15% +$66.7K 0.02% 792
2024
Q4 		$510K Buy
12,265
+836
+7% +$40K 0.03% 537
2024
Q3 		$764K Buy
11,429
+243
+2% +$22.3K 0.04% 397
2024
Q2 		$1.33M Buy
11,186
+282
+3% +$35.7K 0.09% 225
2024
Q1 		$1.16M Sell
10,904
-834
-7% -$84.1K 0.09% 213
2023
Q4 		$1.17M Sell
11,738
-751
-6% -$63.2K 0.1% 194
2023
Q3 		$1.29M Buy
12,489
+86
+0.7% +$9.59K 0.12% 174
2023
Q2 		$1.51M Sell
12,403
-822
-6% -$110K 0.18% 139
2023
Q1 		$2.03M Sell
13,225
-102
-0.8% -$16.8K 0.24% 113
2022
Q4 		$2.39M Sell
13,327
-50
-0.4% -$8.18K 0.32% 87
2022
Q3 		$1.58M Buy
13,377
+350
+3% +$53.1K 0.24% 114
2022
Q2 		$1.86M Buy
13,027
+10
+0.1% +$1.43K 0.28% 98
2022
Q1 		$2.24M Buy
13,017
+911
+8% +$153K 0.29% 87
2021
Q4 		$3.08M Buy
12,106
+309
+3% +$90.3K 0.41% 59
2021
Q3 		$4.54M Buy
11,797
+270
+2% +$99.6K 0.65% 23
2021
Q2 		$2.71M Buy
11,527
+260
+2% +$46.5K 0.33% 77
2021
Q1 		$1.48M Buy
11,267
+3,735
+50% +$541K 0.24% 107
2020
Q4 		$786K Buy
7,532
+996
+15% +$101K 0.16% 138
2020
Q3 		$483K Buy
6,536
+2,686
+70% +$187K 0.24% 94
2020
Q2 		$289K Buy
3,850
+850
+28% +$46.5K 0.16% 131
2020
Q1 		$89.8K Buy
+3,000
New +$69K 0.06% 243

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Arkadios Wealth Advisors's MRNA Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its Moderna (MRNA) stake by 16% in Q2 2026, selling an estimated $146K and leaving 15,033 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #782.

Arkadios Wealth Advisors first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.54M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Arkadios Wealth Advisors held 15,033 shares of Moderna worth $1.05M as of Q2 2026.
  • Arkadios Wealth Advisors sold 2,824 Moderna shares in Q2 2026, an estimated $146K.
  • Moderna made up 0.02% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #782 holding.
  • Arkadios Wealth Advisors first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Arkadios Wealth Advisors's Moderna position peaked at $4.54M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.